PubMed:8755574 JSONTXT

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":131,"end":153},"obj":"gene:5371"},{"id":"T1","span":{"begin":87,"end":115},"obj":"disease:C0023487"},{"id":"T2","span":{"begin":191,"end":219},"obj":"gene:5914"},{"id":"T3","span":{"begin":87,"end":115},"obj":"disease:C0023487"},{"id":"T4","span":{"begin":221,"end":229},"obj":"gene:5914"},{"id":"T5","span":{"begin":87,"end":115},"obj":"disease:C0023487"},{"id":"T6","span":{"begin":510,"end":518},"obj":"gene:5914"},{"id":"T7","span":{"begin":463,"end":491},"obj":"disease:C0023487"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Transgenic expression of PML/RARalpha impairs myelopoiesis.\nThe translocation found in acute promyelocytic leukemia rearranges the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor alpha (RARalpha) on chromosome 17. This yields a fusion transcript, PML/RARalpha, a transcription factor with reported dominant negative functions in the absence of hormone. Clinical remissions induced with all-trans retinoic acid (RA) treatment in acute promyelocytic leukemia are linked to PML/RARalpha expression in leukemic cells. To evaluate the PML/RARalpha role in myelopoiesis, transgenic mice expressing PML/RARalpha were engineered. A full-length PML/RARalpha cDNA driven by the CD11b promoter was expressed in transgenic mice. Expression was confirmed in the bone marrow with a reverse transcription PCR assay. Basal total white blood cell and granulocyte counts did not appreciably differ between PML/RARalpha transgenic and control mice. Cell sorter analysis of CD11b+ bone marrow cells revealed similar CD11b+ populations in transgenic and control mice. However, in vitro clonal growth assays performed on peripheral blood from transgenic versus control mice revealed a marked reduction of myeloid progenitors, especially in those responding to granulocyte/ macrophage colony-stimulating factor. Granulocyte/macrophage colony-stimulating factor and kit ligand cotreatment did not overcome this inhibition. Impaired myelopoiesis in vivo was shown by stressing these mice with sublethal irradiation. Following irradiation, PML/RARalpha transgenic mice, as compared with controls, more rapidly depressed peripheral white blood cell and granulocyte counts. As expected, nearly all control mice (94.4%) survived irradiation, yet this irradiation was lethal to 45.8% of PML/RARalpha transgenic mice. Lethality was associated with more severe leukopenia in transgenic versus control mice. Retinoic acid treatment of irradiated PML/RARalpha mice enhanced granulocyte recovery. These data suggest that abnormal myelopoiesis due to PML/RARalpha expression is an early event in oncogenic transformation."}

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":25,"end":37},"obj":"protein"},{"id":"T2","span":{"begin":131,"end":158},"obj":"DNA"},{"id":"T3","span":{"begin":160,"end":163},"obj":"DNA"},{"id":"T4","span":{"begin":168,"end":181},"obj":"DNA"},{"id":"T5","span":{"begin":191,"end":219},"obj":"DNA"},{"id":"T6","span":{"begin":221,"end":229},"obj":"protein"},{"id":"T7","span":{"begin":234,"end":247},"obj":"DNA"},{"id":"T8","span":{"begin":282,"end":294},"obj":"protein"},{"id":"T9","span":{"begin":298,"end":318},"obj":"protein"},{"id":"T10","span":{"begin":506,"end":518},"obj":"protein"},{"id":"T11","span":{"begin":533,"end":547},"obj":"cell_type"},{"id":"T12","span":{"begin":565,"end":577},"obj":"protein"},{"id":"T13","span":{"begin":627,"end":639},"obj":"protein"},{"id":"T14","span":{"begin":671,"end":688},"obj":"DNA"},{"id":"T15","span":{"begin":703,"end":717},"obj":"DNA"},{"id":"T16","span":{"begin":923,"end":935},"obj":"protein"},{"id":"T17","span":{"begin":989,"end":1013},"obj":"cell_type"},{"id":"T18","span":{"begin":1031,"end":1049},"obj":"cell_type"},{"id":"T19","span":{"begin":1218,"end":1237},"obj":"cell_type"},{"id":"T20","span":{"begin":1273,"end":1322},"obj":"protein"},{"id":"T21","span":{"begin":1324,"end":1372},"obj":"protein"},{"id":"T22","span":{"begin":1549,"end":1561},"obj":"protein"},{"id":"T23","span":{"begin":1792,"end":1804},"obj":"protein"},{"id":"T24","span":{"begin":1948,"end":1960},"obj":"protein"},{"id":"T25","span":{"begin":1975,"end":1986},"obj":"cell_type"},{"id":"T26","span":{"begin":2050,"end":2062},"obj":"protein"}],"text":"Transgenic expression of PML/RARalpha impairs myelopoiesis.\nThe translocation found in acute promyelocytic leukemia rearranges the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor alpha (RARalpha) on chromosome 17. This yields a fusion transcript, PML/RARalpha, a transcription factor with reported dominant negative functions in the absence of hormone. Clinical remissions induced with all-trans retinoic acid (RA) treatment in acute promyelocytic leukemia are linked to PML/RARalpha expression in leukemic cells. To evaluate the PML/RARalpha role in myelopoiesis, transgenic mice expressing PML/RARalpha were engineered. A full-length PML/RARalpha cDNA driven by the CD11b promoter was expressed in transgenic mice. Expression was confirmed in the bone marrow with a reverse transcription PCR assay. Basal total white blood cell and granulocyte counts did not appreciably differ between PML/RARalpha transgenic and control mice. Cell sorter analysis of CD11b+ bone marrow cells revealed similar CD11b+ populations in transgenic and control mice. However, in vitro clonal growth assays performed on peripheral blood from transgenic versus control mice revealed a marked reduction of myeloid progenitors, especially in those responding to granulocyte/ macrophage colony-stimulating factor. Granulocyte/macrophage colony-stimulating factor and kit ligand cotreatment did not overcome this inhibition. Impaired myelopoiesis in vivo was shown by stressing these mice with sublethal irradiation. Following irradiation, PML/RARalpha transgenic mice, as compared with controls, more rapidly depressed peripheral white blood cell and granulocyte counts. As expected, nearly all control mice (94.4%) survived irradiation, yet this irradiation was lethal to 45.8% of PML/RARalpha transgenic mice. Lethality was associated with more severe leukopenia in transgenic versus control mice. Retinoic acid treatment of irradiated PML/RARalpha mice enhanced granulocyte recovery. These data suggest that abnormal myelopoiesis due to PML/RARalpha expression is an early event in oncogenic transformation."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"8755574-1#71#93#gene5371","span":{"begin":131,"end":153},"obj":"gene5371"},{"id":"8755574-1#27#55#diseaseC0023487","span":{"begin":87,"end":115},"obj":"diseaseC0023487"},{"id":"8755574-3#122#130#gene5914","span":{"begin":510,"end":518},"obj":"gene5914"},{"id":"8755574-3#75#103#diseaseC0023487","span":{"begin":463,"end":491},"obj":"diseaseC0023487"}],"relations":[{"id":"71#93#gene537127#55#diseaseC0023487","pred":"associated_with","subj":"8755574-1#71#93#gene5371","obj":"8755574-1#27#55#diseaseC0023487"},{"id":"122#130#gene591475#103#diseaseC0023487","pred":"associated_with","subj":"8755574-3#122#130#gene5914","obj":"8755574-3#75#103#diseaseC0023487"}],"text":"Transgenic expression of PML/RARalpha impairs myelopoiesis.\nThe translocation found in acute promyelocytic leukemia rearranges the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor alpha (RARalpha) on chromosome 17. This yields a fusion transcript, PML/RARalpha, a transcription factor with reported dominant negative functions in the absence of hormone. Clinical remissions induced with all-trans retinoic acid (RA) treatment in acute promyelocytic leukemia are linked to PML/RARalpha expression in leukemic cells. To evaluate the PML/RARalpha role in myelopoiesis, transgenic mice expressing PML/RARalpha were engineered. A full-length PML/RARalpha cDNA driven by the CD11b promoter was expressed in transgenic mice. Expression was confirmed in the bone marrow with a reverse transcription PCR assay. Basal total white blood cell and granulocyte counts did not appreciably differ between PML/RARalpha transgenic and control mice. Cell sorter analysis of CD11b+ bone marrow cells revealed similar CD11b+ populations in transgenic and control mice. However, in vitro clonal growth assays performed on peripheral blood from transgenic versus control mice revealed a marked reduction of myeloid progenitors, especially in those responding to granulocyte/ macrophage colony-stimulating factor. Granulocyte/macrophage colony-stimulating factor and kit ligand cotreatment did not overcome this inhibition. Impaired myelopoiesis in vivo was shown by stressing these mice with sublethal irradiation. Following irradiation, PML/RARalpha transgenic mice, as compared with controls, more rapidly depressed peripheral white blood cell and granulocyte counts. As expected, nearly all control mice (94.4%) survived irradiation, yet this irradiation was lethal to 45.8% of PML/RARalpha transgenic mice. Lethality was associated with more severe leukopenia in transgenic versus control mice. Retinoic acid treatment of irradiated PML/RARalpha mice enhanced granulocyte recovery. These data suggest that abnormal myelopoiesis due to PML/RARalpha expression is an early event in oncogenic transformation."}

{"project":"genia-medco-coref","denotations":[{"id":"C19","span":{"begin":25,"end":37},"obj":"NP"},{"id":"C5","span":{"begin":46,"end":58},"obj":"NP"},{"id":"C2","span":{"begin":261,"end":280},"obj":"NP"},{"id":"C3","span":{"begin":282,"end":294},"obj":"NP"},{"id":"C4","span":{"begin":296,"end":386},"obj":"NP"},{"id":"C17","span":{"begin":506,"end":529},"obj":"NP"},{"id":"C6","span":{"begin":586,"end":598},"obj":"NP"},{"id":"C7","span":{"begin":627,"end":639},"obj":"NP"},{"id":"C8","span":{"begin":600,"end":639},"obj":"NP"},{"id":"C9","span":{"begin":735,"end":750},"obj":"NP"},{"id":"C13","span":{"begin":1156,"end":1186},"obj":"NP"},{"id":"C10","span":{"begin":1273,"end":1322},"obj":"NP"},{"id":"C11","span":{"begin":1324,"end":1372},"obj":"NP"},{"id":"C14","span":{"begin":1487,"end":1497},"obj":"NP"},{"id":"C12","span":{"begin":1549,"end":1577},"obj":"NP"},{"id":"C15","span":{"begin":1792,"end":1820},"obj":"NP"},{"id":"C16","span":{"begin":1878,"end":1908},"obj":"NP"},{"id":"C18","span":{"begin":2050,"end":2073},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-ident","subj":"C2","obj":"C19"},{"id":"R2","pred":"coref-appos","subj":"C3","obj":"C2"},{"id":"R3","pred":"coref-appos","subj":"C4","obj":"C3"},{"id":"R4","pred":"coref-ident","subj":"C6","obj":"C5"},{"id":"R5","pred":"coref-ident","subj":"C7","obj":"C3"},{"id":"R6","pred":"coref-ident","subj":"C9","obj":"C8"},{"id":"R7","pred":"coref-ident","subj":"C11","obj":"C10"},{"id":"R8","pred":"coref-ident","subj":"C14","obj":"C13"},{"id":"R9","pred":"coref-ident","subj":"C12","obj":"C8"},{"id":"R10","pred":"coref-ident","subj":"C15","obj":"C12"},{"id":"R11","pred":"coref-ident","subj":"C16","obj":"C13"},{"id":"R12","pred":"coref-ident","subj":"C18","obj":"C17"}],"text":"Transgenic expression of PML/RARalpha impairs myelopoiesis.\nThe translocation found in acute promyelocytic leukemia rearranges the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor alpha (RARalpha) on chromosome 17. This yields a fusion transcript, PML/RARalpha, a transcription factor with reported dominant negative functions in the absence of hormone. Clinical remissions induced with all-trans retinoic acid (RA) treatment in acute promyelocytic leukemia are linked to PML/RARalpha expression in leukemic cells. To evaluate the PML/RARalpha role in myelopoiesis, transgenic mice expressing PML/RARalpha were engineered. A full-length PML/RARalpha cDNA driven by the CD11b promoter was expressed in transgenic mice. Expression was confirmed in the bone marrow with a reverse transcription PCR assay. Basal total white blood cell and granulocyte counts did not appreciably differ between PML/RARalpha transgenic and control mice. Cell sorter analysis of CD11b+ bone marrow cells revealed similar CD11b+ populations in transgenic and control mice. However, in vitro clonal growth assays performed on peripheral blood from transgenic versus control mice revealed a marked reduction of myeloid progenitors, especially in those responding to granulocyte/ macrophage colony-stimulating factor. Granulocyte/macrophage colony-stimulating factor and kit ligand cotreatment did not overcome this inhibition. Impaired myelopoiesis in vivo was shown by stressing these mice with sublethal irradiation. Following irradiation, PML/RARalpha transgenic mice, as compared with controls, more rapidly depressed peripheral white blood cell and granulocyte counts. As expected, nearly all control mice (94.4%) survived irradiation, yet this irradiation was lethal to 45.8% of PML/RARalpha transgenic mice. Lethality was associated with more severe leukopenia in transgenic versus control mice. Retinoic acid treatment of irradiated PML/RARalpha mice enhanced granulocyte recovery. These data suggest that abnormal myelopoiesis due to PML/RARalpha expression is an early event in oncogenic transformation."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":59},"obj":"Sentence"},{"id":"S2","span":{"begin":60,"end":248},"obj":"Sentence"},{"id":"S3","span":{"begin":249,"end":387},"obj":"Sentence"},{"id":"S4","span":{"begin":388,"end":548},"obj":"Sentence"},{"id":"S5","span":{"begin":549,"end":656},"obj":"Sentence"},{"id":"S6","span":{"begin":657,"end":751},"obj":"Sentence"},{"id":"S7","span":{"begin":752,"end":835},"obj":"Sentence"},{"id":"S8","span":{"begin":836,"end":964},"obj":"Sentence"},{"id":"S9","span":{"begin":965,"end":1081},"obj":"Sentence"},{"id":"S10","span":{"begin":1082,"end":1323},"obj":"Sentence"},{"id":"S11","span":{"begin":1324,"end":1433},"obj":"Sentence"},{"id":"S12","span":{"begin":1434,"end":1525},"obj":"Sentence"},{"id":"S13","span":{"begin":1526,"end":1680},"obj":"Sentence"},{"id":"S14","span":{"begin":1681,"end":1821},"obj":"Sentence"},{"id":"S15","span":{"begin":1822,"end":1909},"obj":"Sentence"},{"id":"S16","span":{"begin":1910,"end":1996},"obj":"Sentence"},{"id":"S17","span":{"begin":1997,"end":2120},"obj":"Sentence"}],"text":"Transgenic expression of PML/RARalpha impairs myelopoiesis.\nThe translocation found in acute promyelocytic leukemia rearranges the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor alpha (RARalpha) on chromosome 17. This yields a fusion transcript, PML/RARalpha, a transcription factor with reported dominant negative functions in the absence of hormone. Clinical remissions induced with all-trans retinoic acid (RA) treatment in acute promyelocytic leukemia are linked to PML/RARalpha expression in leukemic cells. To evaluate the PML/RARalpha role in myelopoiesis, transgenic mice expressing PML/RARalpha were engineered. A full-length PML/RARalpha cDNA driven by the CD11b promoter was expressed in transgenic mice. Expression was confirmed in the bone marrow with a reverse transcription PCR assay. Basal total white blood cell and granulocyte counts did not appreciably differ between PML/RARalpha transgenic and control mice. Cell sorter analysis of CD11b+ bone marrow cells revealed similar CD11b+ populations in transgenic and control mice. However, in vitro clonal growth assays performed on peripheral blood from transgenic versus control mice revealed a marked reduction of myeloid progenitors, especially in those responding to granulocyte/ macrophage colony-stimulating factor. Granulocyte/macrophage colony-stimulating factor and kit ligand cotreatment did not overcome this inhibition. Impaired myelopoiesis in vivo was shown by stressing these mice with sublethal irradiation. Following irradiation, PML/RARalpha transgenic mice, as compared with controls, more rapidly depressed peripheral white blood cell and granulocyte counts. As expected, nearly all control mice (94.4%) survived irradiation, yet this irradiation was lethal to 45.8% of PML/RARalpha transgenic mice. Lethality was associated with more severe leukopenia in transgenic versus control mice. Retinoic acid treatment of irradiated PML/RARalpha mice enhanced granulocyte recovery. These data suggest that abnormal myelopoiesis due to PML/RARalpha expression is an early event in oncogenic transformation."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":0,"end":21},"obj":"other_name"},{"id":"T2","span":{"begin":25,"end":37},"obj":"protein_molecule"},{"id":"T3","span":{"begin":46,"end":58},"obj":"other_name"},{"id":"T4","span":{"begin":87,"end":115},"obj":"other_name"},{"id":"T5","span":{"begin":131,"end":158},"obj":"DNA_domain_or_region"},{"id":"T6","span":{"begin":160,"end":163},"obj":"DNA_domain_or_region"},{"id":"T7","span":{"begin":168,"end":181},"obj":"DNA_molecule"},{"id":"T8","span":{"begin":191,"end":219},"obj":"DNA_domain_or_region"},{"id":"T9","span":{"begin":221,"end":229},"obj":"protein_molecule"},{"id":"T10","span":{"begin":234,"end":247},"obj":"DNA_molecule"},{"id":"T11","span":{"begin":282,"end":294},"obj":"protein_molecule"},{"id":"T12","span":{"begin":298,"end":318},"obj":"protein_family_or_group"},{"id":"T13","span":{"begin":388,"end":407},"obj":"other_name"},{"id":"T14","span":{"begin":421,"end":444},"obj":"other_organic_compound"},{"id":"T15","span":{"begin":446,"end":448},"obj":"other_organic_compound"},{"id":"T16","span":{"begin":463,"end":491},"obj":"other_name"},{"id":"T17","span":{"begin":506,"end":518},"obj":"protein_molecule"},{"id":"T18","span":{"begin":533,"end":547},"obj":"cell_type"},{"id":"T19","span":{"begin":565,"end":577},"obj":"protein_molecule"},{"id":"T20","span":{"begin":586,"end":598},"obj":"other_name"},{"id":"T21","span":{"begin":600,"end":615},"obj":"other_artificial_source"},{"id":"T22","span":{"begin":627,"end":639},"obj":"protein_molecule"},{"id":"T23","span":{"begin":671,"end":683},"obj":"protein_molecule"},{"id":"T24","span":{"begin":703,"end":717},"obj":"DNA_domain_or_region"},{"id":"T25","span":{"begin":735,"end":750},"obj":"other_artificial_source"},{"id":"T26","span":{"begin":784,"end":795},"obj":"tissue"},{"id":"T27","span":{"begin":803,"end":834},"obj":"other_name"},{"id":"T28","span":{"begin":848,"end":864},"obj":"other_name"},{"id":"T29","span":{"begin":869,"end":887},"obj":"other_name"},{"id":"T30","span":{"begin":923,"end":935},"obj":"protein_molecule"},{"id":"T31","span":{"begin":936,"end":946},"obj":"other_artificial_source"},{"id":"T32","span":{"begin":951,"end":963},"obj":"multi_cell"},{"id":"T33","span":{"begin":989,"end":995},"obj":"cell_type"},{"id":"T34","span":{"begin":996,"end":1007},"obj":"tissue"},{"id":"T35","span":{"begin":1031,"end":1049},"obj":"cell_type"},{"id":"T36","span":{"begin":1053,"end":1063},"obj":"other_artificial_source"},{"id":"T37","span":{"begin":1068,"end":1080},"obj":"multi_cell"},{"id":"T38","span":{"begin":1091,"end":1120},"obj":"other_name"},{"id":"T39","span":{"begin":1134,"end":1150},"obj":"tissue"},{"id":"T40","span":{"begin":1156,"end":1166},"obj":"other_artificial_source"},{"id":"T41","span":{"begin":1174,"end":1186},"obj":"multi_cell"},{"id":"T42","span":{"begin":1218,"end":1237},"obj":"cell_type"},{"id":"T43","span":{"begin":1273,"end":1322},"obj":"protein_molecule"},{"id":"T44","span":{"begin":1324,"end":1372},"obj":"protein_molecule"},{"id":"T45","span":{"begin":1377,"end":1399},"obj":"other_name"},{"id":"T46","span":{"begin":1443,"end":1455},"obj":"other_name"},{"id":"T47","span":{"begin":1493,"end":1497},"obj":"multi_cell"},{"id":"T48","span":{"begin":1513,"end":1524},"obj":"other_name"},{"id":"T49","span":{"begin":1536,"end":1547},"obj":"other_name"},{"id":"T50","span":{"begin":1549,"end":1561},"obj":"protein_molecule"},{"id":"T51","span":{"begin":1562,"end":1572},"obj":"other_artificial_source"},{"id":"T52","span":{"begin":1573,"end":1577},"obj":"multi_cell"},{"id":"T53","span":{"begin":1705,"end":1717},"obj":"multi_cell"},{"id":"T54","span":{"begin":1735,"end":1746},"obj":"other_name"},{"id":"T55","span":{"begin":1757,"end":1768},"obj":"other_name"},{"id":"T56","span":{"begin":1792,"end":1804},"obj":"protein_molecule"},{"id":"T57","span":{"begin":1805,"end":1820},"obj":"other_artificial_source"},{"id":"T58","span":{"begin":1864,"end":1874},"obj":"other_name"},{"id":"T59","span":{"begin":1878,"end":1888},"obj":"other_artificial_source"},{"id":"T60","span":{"begin":1896,"end":1908},"obj":"multi_cell"},{"id":"T61","span":{"begin":1910,"end":1923},"obj":"other_organic_compound"},{"id":"T62","span":{"begin":1948,"end":1960},"obj":"protein_molecule"},{"id":"T63","span":{"begin":1975,"end":1986},"obj":"cell_type"},{"id":"T64","span":{"begin":2030,"end":2042},"obj":"other_name"},{"id":"T65","span":{"begin":2050,"end":2062},"obj":"protein_molecule"},{"id":"T66","span":{"begin":2095,"end":2119},"obj":"other_name"}],"text":"Transgenic expression of PML/RARalpha impairs myelopoiesis.\nThe translocation found in acute promyelocytic leukemia rearranges the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor alpha (RARalpha) on chromosome 17. This yields a fusion transcript, PML/RARalpha, a transcription factor with reported dominant negative functions in the absence of hormone. Clinical remissions induced with all-trans retinoic acid (RA) treatment in acute promyelocytic leukemia are linked to PML/RARalpha expression in leukemic cells. To evaluate the PML/RARalpha role in myelopoiesis, transgenic mice expressing PML/RARalpha were engineered. A full-length PML/RARalpha cDNA driven by the CD11b promoter was expressed in transgenic mice. Expression was confirmed in the bone marrow with a reverse transcription PCR assay. Basal total white blood cell and granulocyte counts did not appreciably differ between PML/RARalpha transgenic and control mice. Cell sorter analysis of CD11b+ bone marrow cells revealed similar CD11b+ populations in transgenic and control mice. However, in vitro clonal growth assays performed on peripheral blood from transgenic versus control mice revealed a marked reduction of myeloid progenitors, especially in those responding to granulocyte/ macrophage colony-stimulating factor. Granulocyte/macrophage colony-stimulating factor and kit ligand cotreatment did not overcome this inhibition. Impaired myelopoiesis in vivo was shown by stressing these mice with sublethal irradiation. Following irradiation, PML/RARalpha transgenic mice, as compared with controls, more rapidly depressed peripheral white blood cell and granulocyte counts. As expected, nearly all control mice (94.4%) survived irradiation, yet this irradiation was lethal to 45.8% of PML/RARalpha transgenic mice. Lethality was associated with more severe leukopenia in transgenic versus control mice. Retinoic acid treatment of irradiated PML/RARalpha mice enhanced granulocyte recovery. These data suggest that abnormal myelopoiesis due to PML/RARalpha expression is an early event in oncogenic transformation."}